SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Dr Reddy’s Bets on Generic Semaglutide and Biosimilars

The report says FY27 earnings are expected to decline before a potential recovery in FY28, amid continued growth in domestic formulations offset by lower North American Revlimid sales and weakness in the API business.

DRREDDY

Related stories